<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="a9176c6c-75b8-4701-8e5d-7eb7f30f0004"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ORACEA<sup>®</sup> safely and effectively. See full prescribing information for ORACEA. ORACEA (doxycycline) capsules for oral use.<br/>Initial U.S. Approval: 1967</title>
   <effectiveTime value="20250401"/>
   <setId root="aa15c93a-ff4c-447a-8a21-96da506d8997"/>
   <versionNumber value="19"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="047350186" root="1.3.6.1.4.1.519.1"/>
            <name>Galderma Laboratories, L.P.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="829672745" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent Pharma Solutions, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0299-3822" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="079415560" root="1.3.6.1.4.1.519.1"/>
                        <name>Patheon Manufacturing Services, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="pack"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0299-3822" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="014904112" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent Pharma Solutions, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="label"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0299-3822" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="ID_153cd589-5252-40bc-8a49-c838ee2668ef">
               <id root="03d7f024-93cc-4caf-abbd-c4b9df4f757f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <title>SPL listing data elements section</title>
               <effectiveTime value="20250206"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0299-3822" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ORACEA</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DOXYCYCLINE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="N12000U13O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOXYCYCLINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOXYCYCLINE ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hypromellose, Unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Methacrylic Acid And Ethyl Acrylate Copolymer</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric Oxide Red</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Ferric Oxide Yellow</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Polyethylene Glycol, Unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Titanium Dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sucrose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="150CTM9A3J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Acetyl Triethylhexyl Citrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0299-3822-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20100514"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="4"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43197" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="16"/>
                                          <denominator unit="1" value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="0299-3822-06" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="completed"/>
                                             <effectiveTime>
                                                <low value="20100514"/>
                                                <high value="20181231"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="4"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="8"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0299-3822-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43233" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKAGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20100514"/>
                                          <high value="20181231"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="4"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0299-3822-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20100514"/>
                                    <high value="20181231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="8"/>
                                          <denominator unit="1" value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code/>
                                          <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                          <asContent>
                                             <quantity>
                                                <numerator unit="1" value="12"/>
                                                <denominator unit="1" value="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code code="0299-3822-02" codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                             </containerPackagedProduct>
                                             <subjectOf>
                                                <marketingAct>
                                                   <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                                   <statusCode code="completed"/>
                                                   <effectiveTime>
                                                      <low value="20150201"/>
                                                      <high value="20181231"/>
                                                   </effectiveTime>
                                                </marketingAct>
                                             </subjectOf>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="4"/>
                                          <denominator unit="1" value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code/>
                                          <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                          <asContent>
                                             <quantity>
                                                <numerator unit="1" value="24"/>
                                                <denominator unit="1" value="1"/>
                                             </quantity>
                                             <containerPackagedProduct>
                                                <code code="0299-3822-07" codeSystem="2.16.840.1.113883.6.69"/>
                                                <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                             </containerPackagedProduct>
                                             <subjectOf>
                                                <marketingAct>
                                                   <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                                   <statusCode code="active"/>
                                                   <effectiveTime>
                                                      <low value="20150201"/>
                                                   </effectiveTime>
                                                </marketingAct>
                                             </subjectOf>
                                          </asContent>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20100514"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050805" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GLD;40</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>beige</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="SPLSERV-174d9e3c-335f-4143-8efe-1d2573dc6f92">
                     <text>30-capsule-label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="P56801-1 label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c861a015-ec87-4581-b07b-1ced1d772bf6">
               <id root="9a8755da-1b1d-442f-97ea-7bfb1360446e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ORACEA is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. (<linkHtml href="#ID_f9248fba-425b-4f63-9d1e-81464c7e26f5">1.</linkHtml>1)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                           <br/>This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. (<linkHtml href="#ID_f9e5c4a7-dc4e-4790-9e5f-03629dfffcc9">1.2</linkHtml>) <br/>ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. (<linkHtml href="#ID_f9e5c4a7-dc4e-4790-9e5f-03629dfffcc9">1.2</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f9248fba-425b-4f63-9d1e-81464c7e26f5">
                     <id root="51a53613-42b1-4524-908b-f8ba78e9c101"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Indication</title>
                     <text>
                        <paragraph>ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f9e5c4a7-dc4e-4790-9e5f-03629dfffcc9">
                     <id root="6379fb7a-471e-4759-b150-fe1229d96c10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Limitations of Use</title>
                     <text>
                        <paragraph>This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated.<br/>
                        </paragraph>
                        <paragraph>ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2c1518c2-edce-4dc5-9f8b-d53b6d079f86">
               <id root="e75bd163-4bf0-4471-93c1-13c682310418"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Take one ORACEA capsule (40 mg) once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals. (<linkHtml href="#ID_24f946c7-c936-4cdc-9f5a-e311eb75c478">2.1</linkHtml>) <br/>Exceeding the recommended dosage may result in an increased incidence of side effects including the development of resistant microorganisms. (<linkHtml href="#ID_ae01f1f8-ebb0-45b7-a5a8-f266be82f07d">2.2</linkHtml>, <linkHtml href="#ID_df20d1a0-eae0-40c6-b2e6-9b8783abc87a">5.9</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_24f946c7-c936-4cdc-9f5a-e311eb75c478">
                     <id root="e1468675-4f1d-4963-8125-021566a53740"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Dosing Information</title>
                     <text>
                        <paragraph>Take one ORACEA capsule (40 mg) once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals. Administration of adequate amounts of fluid along with the capsules is recommended to wash down the capsule to reduce the risk of esophageal irritation and ulceration [<content styleCode="italics">
                              <linkHtml href="#ID_9cf955e8-769c-4a12-a97c-9427888ba1b2">see Adverse Reactions (6)</linkHtml>
                           </content>].<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ae01f1f8-ebb0-45b7-a5a8-f266be82f07d">
                     <id root="73d15654-88b3-4811-aaf1-9c0b6d7a5871"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Important Considerations for Dosing Regimen</title>
                     <text>
                        <paragraph>The dosage of ORACEA differs from that of doxycycline used to treat infections. Exceeding the recommended dosage may result in an increased incidence of side effects including the development of resistant organisms.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a903dc34-dcc0-4d02-92ab-6f4343610047">
               <id root="6f24dd42-997c-4428-b106-c579c4572076"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>40 mg beige opaque capsule imprinted with “GLD 40”</paragraph>
               </text>
               <effectiveTime value="20220930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>40 mg capsule. (<linkHtml href="#ID_a903dc34-dcc0-4d02-92ab-6f4343610047">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_7a097258-63f5-4af3-8164-03d0d062536a">
               <id root="95d28ba6-78cc-437e-b26d-4cb7629e295f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>​This drug is contraindicated in persons who have shown hypersensitivity to doxycycline or any of the other tetracyclines.</paragraph>
               </text>
               <effectiveTime value="20220930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ORACEA is contraindicated in persons who have shown hypersensitivity to doxycycline or other tetracyclines. (<linkHtml href="#ID_7a097258-63f5-4af3-8164-03d0d062536a">4</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_ee0612d8-6689-4f04-a0ad-2e687d0d2ace">
               <id root="f2241ac4-db58-41f7-8c6c-2cd0974f0843"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>The use of ORACEA during tooth development (the second and third trimesters of pregnancy, infancy and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and reversible inhibition of bone growth. (<linkHtml href="#ID_627d314d-b5dd-49b3-a9f0-30af9532ce4c">5.1</linkHtml>, <linkHtml href="#ID_1c84d3f7-9505-47a4-b7cc-af5105a24210">5.2</linkHtml>, <linkHtml href="#ID_60395afe-27d9-4944-a5ac-d53a577ee1f2">8.1</linkHtml>, <linkHtml href="#ID_4556acb6-f786-4e3f-ae0b-3ef84f513322">8.4</linkHtml>) </item>
                           <item>Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">Clostridium difficile</content>. If <content styleCode="italics">C. difficile</content> associated diarrhea occurs, discontinue ORACEA. (<linkHtml href="#ID_6cb65e46-d97f-4a94-bdd6-eea46ad9e2d3">5.3</linkHtml>) </item>
                           <item>If renal impairment exists, ORACEA doses may need to be adjusted to avoid excessive systemic accumulations of the drug and possible liver injury. (<linkHtml href="#ID_e6265c07-dfe9-429f-9c81-2c45e691eab1">5.4</linkHtml>)<br/>
                           </item>
                           <item>Photosensitivity can occur with ORACEA; Patients should minimize or avoid exposure to natural or artificial sunlight. (<linkHtml href="#ID_36d84ca4-fc8b-4c55-9a4d-25f9dea65325">5.5</linkHtml>)<br/>
                           </item>
                           <item>Tetracyclines have been associated with the development of autoimmune syndromes; if symptoms develop, discontinue ORACEA immediately. (<linkHtml href="#ID_238b65e5-c0da-41aa-9edd-837f89ed34cd">5.6</linkHtml>)<br/>
                           </item>
                           <item>ORACEA may cause pseudotumor cerebri (benign intracranial hypertension). Discontinue ORACEA if symptoms occur. (<linkHtml href="#ID_74aca62e-65c4-4d69-baf0-cba885e61a5c">5.8</linkHtml>)<br/>
                           </item>
                           <item>Bacterial resistance to tetracyclines may develop in patients using ORACEA. It should only be used as indicated. (<linkHtml href="#ID_df20d1a0-eae0-40c6-b2e6-9b8783abc87a">5.9</linkHtml>)<br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_627d314d-b5dd-49b3-a9f0-30af9532ce4c">
                     <id root="123612a6-8421-4d34-ab76-d92ece50f6ad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Inhibition of Bone Growth During Fetal and Pediatric Development</title>
                     <text>
                        <paragraph>Doxycycline, like other tetracycline-class drugs, may cause inhibition of bone growth when administered during the second and third trimesters of pregnancy, infancy, and childhood. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. If doxycycline is used during the second or third trimester of pregnancy, advise the patient of the potential risk to the fetus [<content styleCode="italics">
                              <linkHtml href="#ID_60395afe-27d9-4944-a5ac-d53a577ee1f2">see Use in Specific Populations (8.1)</linkHtml>
                           </content>].<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1c84d3f7-9505-47a4-b7cc-af5105a24210">
                     <id root="d098e263-e25c-4fe8-b26f-21ce2c7eb787"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Tooth Discoloration During Fetal and Pediatric Development</title>
                     <text>
                        <paragraph>The use of tetracycline class drugs orally during tooth development (last half of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use of tetracycline drugs is not recommended during tooth development [<content styleCode="italics">
                              <linkHtml href="#ID_60395afe-27d9-4944-a5ac-d53a577ee1f2">see Use in Specific Populations (8.1)</linkHtml>
                           </content>].<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6cb65e46-d97f-4a94-bdd6-eea46ad9e2d3">
                     <id root="aff7eb32-98a1-4f7f-a47e-94ae4058009d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 <content styleCode="italics">Clostridium difficile</content> Associated Diarrhea (CDAD)</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridium difficile</content> associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>. <br/>
                           <br/>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.<br/>
                           <br/> If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate management should be instituted as clinically indicated.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e6265c07-dfe9-429f-9c81-2c45e691eab1">
                     <id root="fa4df511-b472-4471-89eb-719c3caa50f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Metabolic Effects</title>
                     <text>
                        <paragraph>The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline-class antibiotics may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated, and if therapy is prolonged, serum level determinations of the drug may be advisable.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_36d84ca4-fc8b-4c55-9a4d-25f9dea65325">
                     <id root="4da10cab-f398-4214-b936-ee26b3d516f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Photosensitivity</title>
                     <text>
                        <paragraph>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Although this was not observed during the duration of the clinical studies with ORACEA, patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using ORACEA. If patients need to be outdoors while using ORACEA, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_238b65e5-c0da-41aa-9edd-837f89ed34cd">
                     <id root="b291ee82-c8b8-49a6-b3dd-ba69fbf3b6e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Autoimmune Syndromes</title>
                     <text>
                        <paragraph>Tetracyclines have been associated with the development of autoimmune syndromes. Symptoms may be manifested by fever, rash, arthralgia, and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. Use of all tetracycline-class drugs should be discontinued immediately.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a026171-0cd1-41e2-95c1-2589c40bb934"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Tissue Hyperpigmentation</title>
                     <text>
                        <paragraph>Tetracycline-class drugs are known to cause hyperpigmentation. Tetracycline therapy may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. Skin and oral pigmentation has been reported to occur independently of time or amount of drug administration, whereas other pigmentation has been reported to occur upon prolonged administration. Skin pigmentation includes diffuse pigmentation as well as over sites of scars or injury.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_74aca62e-65c4-4d69-baf0-cba885e61a5c">
                     <id root="b0275f0c-c4a4-42c9-ad76-82add9d92e6c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Pseudotumor Cerebri</title>
                     <text>
                        <paragraph>Pseudotumor cerebri (benign intracranial hypertension) in adults has been associated with the use of tetracyclines. The usual clinical manifestations are headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines in infants. While both of these conditions and related symptoms usually resolve after discontinuation of the tetracycline, the possibility for permanent sequelae exists. Patients should be questioned for visual disturbances prior to initiation of treatment with tetracyclines and should be routinely checked for papiledema while on treatment.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_df20d1a0-eae0-40c6-b2e6-9b8783abc87a">
                     <id root="44b90fbd-977e-4f58-883c-329e7ee36d18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Development of Drug Resistant Bacteria</title>
                     <text>
                        <paragraph>Bacterial resistance to tetracyclines may develop in patients using ORACEA. Because of the potential for drug-resistant bacteria to develop during the use of ORACEA, it should only be used as indicated.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="47b352ef-4387-4478-ab8c-eeecba4dc837"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Superinfection</title>
                     <text>
                        <paragraph>As with other antibiotic preparations, use of ORACEA may result in overgrowth of non-susceptible microorganisms, including fungi. If superinfection occurs, ORACEA should be discontinued and appropriate therapy instituted. Although not observed in clinical trials with ORACEA, the use of tetracyclines may increase the incidence of vaginal candidiasis. ORACEA should be used with caution in patients with a history of or predisposition to<content styleCode="italics"> Candida</content> overgrowth.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c2559832-6a78-4447-9ea8-daf940ca0377">
                     <id root="85f82f6a-f6b2-4616-9b74-0a884446fdb6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Laboratory Monitoring</title>
                     <text>
                        <paragraph>Periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic studies should be performed. Appropriate tests for autoimmune syndromes should be performed as indicated.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f64c1f9f-07f3-4659-9b94-dbf027768711">
                     <id root="ac6c08e9-19a1-4c86-bbe9-157983b1a5bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Fixed Drug Eruption</title>
                     <text>
                        <paragraph>Fixed drug eruptions have occurred with doxycycline and have been associated with worsening severity upon subsequent administrations, including generalized bullous fixed drug eruption [see Adverse Reactions (6.2)].  If severe reactions occur, discontinue ORACEA immediately and initiate appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9cf955e8-769c-4a12-a97c-9427888ba1b2">
               <id root="380feb54-769a-4263-8879-e7d0e34ed328"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text/>
               <effectiveTime value="20250404"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Some of the most common adverse reactions (incidence &gt;2% and more common than with placebo) are nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. (<linkHtml href="#ID_9cf955e8-769c-4a12-a97c-9427888ba1b2">6</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Galderma Laboratories, L.P. at 1-866-735-4137 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c7a6e036-aa94-4bee-8020-c7c8e00d9968">
                     <id root="e6a3aa3a-8b5b-47d6-a6ad-62e677dd421f"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Adverse Reactions in Clinical Trials of ORACEA:</content> In controlled clinical trials of adult subjects with mild to moderate rosacea, 537 subjects received ORACEA or placebo over a 16-week period. The following table summarizes selected adverse reactions that occurred in the clinical trials at a rate of ≥1% for the active arm:</paragraph>
                        <table border="1" cellpadding="4" cellspacing="0" width="50%">
                           <caption>Table 1.  Incidence (%) of Selected Adverse Reactions in Clinical Trials of ORACEA (n=269) v.s. Placebo (n=268)</caption>
                           <colgroup>
                              <col/>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">ORACEA</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">Placebo</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Nasopharyngitis</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">13 (5)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">9 (3)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Pharyngolaryngeal Pain</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Sinusitis</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">7 (3)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Nasal Congestion</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">4 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Fungal Infection</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">5 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Influenza</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">5 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Diarrhea</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">12 (5)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">7 (3)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Abdominal Pain Upper</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">5 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Abdominal Distention</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Abdominal Pain</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Stomach Discomfort</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Dry Mouth</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">0 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Hypertension</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">8 (3)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Blood Pressure Increase</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">4 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Aspartate Aminotransferase Increase</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">6 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2 (1)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Blood Lactate Dehydrogenase Increase</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">4 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Blood Glucose Increase</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">0 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Anxiety</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">4 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">0 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Pain</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">4 (2)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">1 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Back Pain</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">0 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Botrule Lrule Rrule Toprule">Sinus Headache</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3 (1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">0 (0)</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" styleCode="Botrule Lrule Rrule Toprule">Note: Percentages based on total number of study participants in each treatment group.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Adverse Reactions for Tetracyclines:</content> The following adverse reactions have been observed in patients receiving tetracyclines at higher, antimicrobial doses:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with vaginal candidiasis) in the anogenital region. Hepatotoxicity, Esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the drugs in the tetracycline-class. Most of the patients experiencing esophagitis and/or esophageal ulceration took their medication immediately before lying down [<content styleCode="italics">
                              <linkHtml href="#ID_2c1518c2-edce-4dc5-9f8b-d53b6d079f86">see Dosage and Administration (2)</linkHtml>
                           </content>].<br/>
                           <br/>
                           <content styleCode="italics"> Renal toxicity:</content> Rise in BUN has been reported and is apparently dose-related [<content styleCode="italics">
                              <linkHtml href="#ID_e6265c07-dfe9-429f-9c81-2c45e691eab1">see Warnings and Precautions (5.4)</linkHtml>
                           </content>]. <br/>
                           <br/>
                           <content styleCode="italics">Skin:</content> maculopapular and erythematous rashes. Exfoliative dermatitis. Photosensitivity is discussed above <content styleCode="italics">[<linkHtml href="#ID_36d84ca4-fc8b-4c55-9a4d-25f9dea65325">see Warnings and Precautions (5.5)</linkHtml>
                           </content>]. <br/>
                           <br/>
                           <content styleCode="italics">Hypersensitivity reactions:</content> urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus. <br/>
                           <br/>
                           <content styleCode="italics">Blood:</content> Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ecc40844-40a9-4db3-a15c-2d5831134e10">
                     <id root="f2cec5f9-82e9-47a7-b65e-23fff9903a07"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Adverse Reactions</title>
                     <text>
                        <paragraph>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of ORACEA.<br/>
                           <content styleCode="italics">
                              <br/>Nervous system</content>: Pseudotumor cerebri (benign intracranial hypertension), headache.<br/>
                           <br/>
                           <content styleCode="italics">Skin</content>: fixed drug eruption<br/>
                           <br/>
                           <content styleCode="italics">Psychiatric</content>: depression, anxiety, suicidal ideation, insomnia, abnormal dreams, hallucination<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250404"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_75650ddd-521b-446c-84ca-b40379f78d25">
               <id root="1beb2144-034e-4322-944f-64529a92a326"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20220930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. (<linkHtml href="#ID_247aa234-e73c-4952-b4aa-5d1b2c2756e8">7.1</linkHtml>)</item>
                           <item> Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. (<linkHtml href="#ID_c50430b3-4396-463d-bc61-032323a18f69">7.2</linkHtml>)  </item>
                           <item>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. (<linkHtml href="#ID_70783b2d-6532-4637-8288-3f0f3110448d">7.3</linkHtml>) <br/>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_247aa234-e73c-4952-b4aa-5d1b2c2756e8">
                     <id root="9973065f-12a6-40e5-9e23-da6cecbb3a68"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1  Anticoagulants</title>
                     <text>
                        <paragraph>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c50430b3-4396-463d-bc61-032323a18f69">
                     <id root="d397db90-4def-4067-be22-cb58996593bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2  Penicillin</title>
                     <text>
                        <paragraph>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_70783b2d-6532-4637-8288-3f0f3110448d">
                     <id root="401db1fb-4d6b-45a5-8b4a-8e7a59474d93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Methoxyflurane</title>
                     <text>
                        <paragraph>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ec9add51-bf64-4f3c-a22e-4143ee8e8c98"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4  Antacids and Iron Preparations</title>
                     <text>
                        <paragraph>Absorption of tetracyclines is impaired by bismuth subsalicylate, proton pump inhibitors, antacids containing aluminum, calcium or magnesium and iron-containing preparations.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1237fb66-79c2-4689-b8b3-f23b9ff32dc6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Oral Retinoids</title>
                     <text>
                        <paragraph>There have been reports of pseudotumor cerebri (benign intracranial hypertension) associated with the concomitant use of isotretinoin and tetracyclines. Since both oral retinoids, including isotretinoin and acitretin, and the tetracyclines, primarily minocycline, can cause increased intracranial pressure, the concurrent use of an oral retinoid and a tetracycline should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="247c952c-4907-4929-b3a7-86cad684d53a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Barbiturates and Anti-epileptics</title>
                     <text>
                        <paragraph>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline. </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="27cd7be2-1de0-4669-ab4f-4ab06f98947a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7 Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f1eb5bcd-1436-46ce-82ea-382948cbae88">
               <id root="763bc668-a07c-4584-8d10-7761ccb25a54"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20220930"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Breastfeeding is not recommended (<linkHtml href="#ID_15552790-db99-4444-9438-e15e0777b491">8.2</linkHtml>)<br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_60395afe-27d9-4944-a5ac-d53a577ee1f2">
                     <id root="06616557-9a01-477f-90e4-197e90a16c3f"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Doxycycline may cause reversible inhibition of bone growth and permanent discoloration of deciduous teeth when administered during the second and third trimesters of pregnancy [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#ID_627d314d-b5dd-49b3-a9f0-30af9532ce4c">5.1</linkHtml> and <linkHtml href="#ID_1c84d3f7-9505-47a4-b7cc-af5105a24210">5.2</linkHtml>)</content>]. Available data from published studies have not shown a difference in major birth defect risk with doxycycline exposure in the first trimester of pregnancy compared to unexposed pregnancies. Avoid use of ORECEA during the second and third trimester of pregnancy. <br/>
                           <br/>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. <br/>
                           <br/>
                           <content styleCode="underline">Data <br/>
                           </content>
                           <content styleCode="italics">Human Data <br/>
                           </content>Published studies, including epidemiological and observational studies, with use of doxycycline during the first trimester of pregnancy have not identified drug-related increases in major birth defects. <br/>
                           <br/>The use of tetracycline during tooth development (second and third trimester of pregnancy) may cause permanent discoloration of deciduous teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drug but has been observed following repeated short- term courses. <br/>
                           <content styleCode="italics">
                              <br/>Animal Data</content>
                           <br/>Results from animal studies indicate that doxycycline crosses the placenta and is found in fetal tissues.<br/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_15552790-db99-4444-9438-e15e0777b491">
                     <id root="7c3e497e-e240-4aa3-b969-b6dee5671461"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Based on available published data, doxycycline is likely to be present in human breast milk but the specific concentration in breastmilk is not clear. There is no information on the effects of doxycycline on the breastfed infant or the effects on milk production. Because there are other antibacterial drug options available to treat rosacea in lactating women and because of the potential for serious adverse reactions, including tooth discoloration and inhibition of bone growth, advise patients that breastfeeding is not recommended during treatment with ORACEA and for 5 days after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4556acb6-f786-4e3f-ae0b-3ef84f513322">
                     <id root="e05c467a-ad1d-452a-88eb-25dcb1fb3188"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>ORACEA should not be used in infants and children less than 8 years of age [<content styleCode="italics">
                              <linkHtml href="#ID_627d314d-b5dd-49b3-a9f0-30af9532ce4c">see Warnings and Precautions (5.1)</linkHtml>
                           </content>]. ORACEA has not been studied in children of any age with regard to safety or efficacy, therefore use in children is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b933afff-7275-413d-b878-fae7bae68ce1">
                     <id root="d40d4202-3cc5-4214-bbfe-4f0ba8f7d1d5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ORACEA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c0042718-0490-4102-a8be-6c91866331e9">
               <id root="89a3c751-a1f1-462f-9b54-987ac1cbc6f9"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ORACEA (doxycycline, USP) Capsules 40 mg are hard gelatin capsule shells filled with two types of doxycycline beads (30 mg immediate release and 10 mg delayed release) that together provide a dose of 40 mg of anhydrous doxycycline (C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>).</paragraph>
                  <paragraph>The structural formula of doxycycline, USP is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="SPLSERV-79952d9d-fe7a-4f80-84c7-94670825dc2f"/>
                  </paragraph>
                  <paragraph>with an empirical formula of C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>•H<sub>2</sub>O and a molecular weight of 462.46. The chemical designation for doxycycline is 2-Naphthacenecar-boxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4α, 4aα, 5α, 5aα, 6α,12aα)]-, monohydrate. It is very slightly soluble in water.</paragraph>
                  <paragraph>Inert ingredients in the formulation are: hard gelatin capsule, hypromellose, methacrylic acid copolymer, Opadry beige, sugar spheres, talc, and triethyl citrate.</paragraph>
               </text>
               <effectiveTime value="20220930"/>
               <component>
                  <observationMedia ID="SPLSERV-79952d9d-fe7a-4f80-84c7-94670825dc2f">
                     <text>oracea-chem-struct</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="oracea-chem-struct.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a414ab7b-4b5a-4388-b110-8484cd3ba813">
               <id root="9ab04122-fe9e-476d-911b-79a036270518"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20220930"/>
               <component>
                  <section>
                     <id root="ebacdc97-fba6-49b4-9a3a-708e66b1dff7"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The mechanism of action of ORACEA in the treatment of inflammatory lesions of rosacea is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9691b05c-68ad-45cf-9366-3802f8b1ab5a">
                     <id root="56d29055-47fe-47dd-9c78-f9ac0b7c2646"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>ORACEA capsules are not bioequivalent to other doxycycline products. The pharmacokinetics of doxycycline following oral administration of<br/>ORACEA was investigated in 2 volunteer studies involving 61 adults. Pharmacokinetic parameters for ORACEA following single oral doses and at steady-state in healthy subjects are presented in Table 2.</paragraph>
                        <table border="1" cellpadding="4" cellspacing="0">
                           <caption>Table 2.  Pharmcokinetic Parameters [Mean (± SD)] for ORACEA</caption>
                           <colgroup>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">N</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">C<sub>max </sub>
                                    <footnote ID="SPLSERV-6a517f71-8d69-492f-a2e5-65b485d70099">Mean</footnote>
                                    <br/>
                                    <sub>(ng/mL)</sub>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">T<sub>max   </sub>
                                    <footnote ID="SPLSERV-e1411d5d-0ff0-4457-a01d-50d726dee6f9">Median</footnote> (hr)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">AU<sub>0-∞</sub>  <footnoteRef IDREF="SPLSERV-6a517f71-8d69-492f-a2e5-65b485d70099"/>
                                    <br/>(ng●hr/mL)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">t<sub>½  </sub> <footnoteRef IDREF="SPLSERV-6a517f71-8d69-492f-a2e5-65b485d70099"/> (hr)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Single Dose<br/>40 mg<br/>capsules</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">30</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">510 ± 220.7</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">3.00<br/>(1.0 - 4.1)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">9227 ±<br/>3212.8</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">21.2 ± 7.6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule">Steady-State <footnote ID="SPLSERV-8bd7f2c1-cf70-4104-bd4e-223cfd86346c">Day 7</footnote>
                                    <br/>40 mg capsules</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">31</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">600 ± 194.2 </td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">2.00<br/>(1.0 - 4.0)</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">7543 ± <br/>2443.9</td>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">23.2 ± 6.2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Absorption:</content>
                           </content> In a single-dose food-effect study involving administration of ORACEA to healthy volunteers, concomitant administration with a 1000 calorie, high-fat, high-protein meal that included dairy products, resulted in a decrease in the rate and extent of absorption (C<sub>max</sub> and AUC) by about 45% and 22%, respectively, compared to dosing under fasted conditions. This decrease in systemic exposure can be clinically significant, and therefore if ORACEA is taken close to meal times, it is recommended that it be taken at least one hour prior to or two hours after meals.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Distribution:</content>
                           </content> Doxycycline is greater than 90% bound to plasma proteins.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolism:</content>
                           </content> Major metabolites of doxycycline have not been identified. However, enzyme inducers such as barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Excretion:</content>
                           </content> Doxycycline is excreted in the urine and feces as unchanged drug. It is reported that between 29% and 55.4% of an administered dose can be accounted for in the urine by 72 hours. Terminal half-life averaged 21.2 hours in subjects receiving a single dose of ORACEA.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Special Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Geriatric:</content>
                           </content> Doxycycline pharmacokinetics have not been evaluated in geriatric patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Pediatric:</content>
                           </content> Doxycycline pharmacokinetics have not been evaluated in pediatric patients [<content styleCode="italics">see <linkHtml href="#ID_627d314d-b5dd-49b3-a9f0-30af9532ce4c">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gender:</content>
                           </content> The pharmacokinetics of ORACEA were compared in 16 male and 14 female subjects under fed and fasted conditions. While female subjects had a higher C<sub>max </sub>and AUC than male subjects, these differences were thought to be due to differences in body weight/lean body mass.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Race:</content>
                           </content> Differences in doxycycline pharmacokinetics among racial groups have not been evaluated.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Renal Insufficiency:</content>
                           </content> Studies have shown no significant difference in serum half-life of doxycycline in patients with normal and severely impaired renal function. Hemodialysis does not alter the serum half-life of doxycycline.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Hepatic Insufficiency:</content>
                           </content> Doxycycline pharmacokinetics have not been evaluated in patients with hepatic insufficiency.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Gastric Insufficiency:</content>
                           </content>In a study in healthy volunteers (N=24) the bioavailability of doxycycline is reported to be reduced at high pH. This reduced bioavailability may be clinically significant in patients with gastrectomy, gastric bypass surgery or who are otherwise deemed achlorhydric.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Drug Interactions:</content>
                           </content> [<content styleCode="italics">see <linkHtml href="#ID_75650ddd-521b-446c-84ca-b40379f78d25">Drug Interactions (7)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0f8aaf35-4b1f-41a5-8bce-90f14bdda48d">
                     <id root="9a398bde-f83f-4f57-9451-2410b4ede8ef"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>Doxycycline is a member of the tetracycline-class of drugs. The plasma concentrations of doxycycline achieved with ORACEA during administration [<content styleCode="italics">see <linkHtml href="#ID_9691b05c-68ad-45cf-9366-3802f8b1ab5a">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics"> </content>and <content styleCode="italics">
                              <linkHtml href="#ID_ae01f1f8-ebb0-45b7-a5a8-f266be82f07d">Dosage and Administration (2.2)</linkHtml>
                           </content>] are less than the concentration required to treat bacterial diseases. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease [<content styleCode="italics">see <linkHtml href="#ID_f9e5c4a7-dc4e-4790-9e5f-03629dfffcc9">Indications and Usage (1.2)</linkHtml>
                           </content>].  <content styleCode="italics">In vivo</content> microbiological studies utilizing a similar drug exposure for up to 18 months demonstrated no detectable long term effects on bacterial flora of the oral cavity, skin, intestinal tract and vagina.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7a52428e-186a-407f-99f6-113b48a731e7">
               <id root="cfa2bcd2-8b61-451a-ad36-f4e64f0048ce"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20220930"/>
               <component>
                  <section>
                     <id root="a4223a2d-7d8e-4e66-b0f2-b52fb754a5cd"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Doxycycline was assessed for potential to induce carcinogenesis in a study in which the compound was administered to Sprague-Dawley rats by gavage at dosages of 20, 75, and 200 mg/kg/day for two years. An increased incidence of uterine polyps was observed in female rats that received 200 mg/kg/day, a dosage that resulted in a systemic exposure to doxycycline approximately 12.2 times that observed in female humans who use ORACEA [exposure comparison based upon area under the curve (AUC) values]. No impact upon tumor incidence was observed in male rats up to at 200 mg/kg/day, or in females at the lower dosages studied.</paragraph>
                        <paragraph>Doxycyline was assessed for potential to induce carcinogenesis in CD-1 mice by gavage at dosages 20, 75, and 150 mg/kg/day in males and at dosages of 20, 100, and 300 mg/kg/day in females. No impact upon tumor incidence was observed in male and female mice at systemic exposures approximately 4.2 and 8.3 times that observed in humans, respectively.</paragraph>
                        <paragraph>Doxycycline demonstrated no potential to cause genetic toxicity in an <content styleCode="italics">in vitro </content>point mutation study with mammalian cells (CHO/HGPRT forward mutation assay) or in an <content styleCode="italics">in vivo</content> micronucleus assay conducted in CD-1 mice. However, data from an <content styleCode="italics">in vitro</content> mammalian chromosomal aberration assay conducted with CHO cells suggest that doxycycline is a weak clastogen. Oral administration of doxycycline to male and female Sprague-Dawley rats adversely affected fertility and reproductive performance, as evidenced by increased time for mating to occur, reduced sperm motility, velocity, and concentration, abnormal sperm morphology, and increased pre-and post-implantation losses. Doxycycline induced reproductive toxicity at all dosages that were examined in this study, as even the lowest dosage tested (50 mg/kg/day) induced a statistically significant reduction in sperm velocity. Note that 50 mg/kg/day is approximately 3.6 times the amount of doxycycline contained in the recommended daily dose of ORACEA when compared on the basis of AUC estimates. Although doxycycline impairs the fertility of rats when administered at sufficient dosage, the effect of ORACEA on human fertility is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20220930"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5267ede5-12c0-4c2a-af3e-fe5e67e9731d">
               <id root="2c3f1ff3-c558-4a82-942a-5064921a440b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The safety and efficacy of ORACEA in the treatment of only inflammatory lesions (papules and pustules) of rosacea was evaluated in two randomized, placebo-controlled, multi-centered, double-blind, 16-week Phase 3 trials involving 537 subjects (total of 269 subjects on ORACEA from the two trials) with rosacea (10 to 40 papules and pustules and two or fewer nodules). Mean baseline lesion counts were 20 and 21 for ORACEA and placebo subject groups respectively. Pregnant and nursing women, subjects &lt;18 years of age, and subjects with ocular rosacea and/or blepharitis/meibomianitis who require ophthalmologic treatment were excluded from trials.</paragraph>
                  <paragraph>At Week 16, subjects in the ORACEA group were evaluated using co-primary endpoints of mean reduction in lesion counts and a dichotomized static Investigator’s Global Assessment of Clear or Almost Clear (defined as 1 to 2 small papules or pustules) when compared to the placebo group in both Phase 3 trials.</paragraph>
                  <table border="1" cellpadding="4" cellspacing="0">
                     <caption>Table 3: Clinical Results of ORACEA versus Placebo</caption>
                     <colgroup>
                        <col/>
                        <col width="15%"/>
                        <col width="15%"/>
                        <col width="15%"/>
                        <col width="15%"/>
                     </colgroup>
                     <tbody styleCode="HeadlessHeadlessHeadless">
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule">Study 1</td>
                           <td align="center" colspan="2" styleCode="Botrule Lrule Rrule Toprule">Study 2</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">ORACEA</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Placebo</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">ORACEA</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">Placebo</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule"/>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">40 mg<br/>N=127</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">N=124</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">40 mg<br/>N=142</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">N=144</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">Mean Change in Lesion Count from Baseline</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">- 11.8</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">- 5.9</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">- 9.5</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">- 4.3</td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule">No. (%) of Subjects Clear or Almost Clear in the IGA <footnote>Investigator's Global Assessment</footnote>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">39 (30.7%)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">24 (19.4%)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">21 (14.8%)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">9 (6.3%)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Subjects treated with ORACEA did not demonstrate significant improvement in erythema when compared to those treated with placebo.</paragraph>
               </text>
               <effectiveTime value="20220930"/>
            </section>
         </component>
         <component>
            <section ID="ID_561804a2-acee-4676-9e88-6122fb27e751">
               <id root="fab73edd-a783-448d-a5f2-085d2d1d3318"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>ORACEA (beige opaque capsule imprinted with “GLD 40”) containing doxycycline, USP in an amount equivalent to 40 mg of anhydrous doxycycline.</paragraph>
                  <paragraph>Bottle of 30 (NDC 0299-3822-30).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>
                  </paragraph>
                  <paragraph>All products are to be stored at controlled room temperatures of 59°F - 86°F (15°C - 30°C) and dispensed in tight, light-resistant containers (USP).</paragraph>
                  <paragraph>Keep out of reach of children.</paragraph>
               </text>
               <effectiveTime value="20220930"/>
            </section>
         </component>
         <component>
            <section ID="ID_f6980786-8083-4c94-9908-baddfa5bf862">
               <id root="11580b80-ad7a-4189-b59b-351577b8e0ab"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>See FDA-approved patient labeling (Patient Information)</paragraph>
                  <paragraph>Patients taking ORACEA Capsules 40 mg should receive the following information and instructions:</paragraph>
                  <list listType="unordered">
                     <item>Advise pregnant women that doxycycline, like other tetracycline-class drugs, may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#ID_627d314d-b5dd-49b3-a9f0-30af9532ce4c">5.1</linkHtml> and <linkHtml href="#ID_1c84d3f7-9505-47a4-b7cc-af5105a24210">5.2</linkHtml>) and Use in Specific Populations (<linkHtml href="#ID_60395afe-27d9-4944-a5ac-d53a577ee1f2">8.1</linkHtml>)</content>]. </item>
                     <item>Advise women not to breastfeed during treatment with ORACEA and for 5 days after the last dose [<content styleCode="italics">see Use in Specific Populations (<linkHtml href="#ID_15552790-db99-4444-9438-e15e0777b491">8.2</linkHtml>)</content>]. </item>
                     <item>Advise patients that use of tetracycline class drugs orally during tooth development (infancy and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). </item>
                     <item>Advise patients that use of doxycycline, like other tetracycline-class drugs, may cause inhibition of bone growth when administered during infancy and childhood. </item>
                     <item>Advise patients that pseudomembranous colitis can occur with doxycycline therapy. If patients develop watery or bloody stools, they should seek medical attention. </item>
                     <item>Advise patients that pseudotumor cerebri can occur with doxycycline therapy. If patients experience headache or blurred vision they should seek medical attention. </item>
                     <item>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines, including doxycycline. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using doxycycline. If patients need to be outdoors while using doxycycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be discontinued at the first evidence of sunburn.</item>
                     <item>Autoimmune syndromes, including drug-induced lupus-like syndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline-class drugs, including doxycycline. Symptoms may be manifested by arthralgia, fever, rash and malaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help. </item>
                     <item>Counsel patients about discoloration of skin, scars, teeth or gums that can arise from doxycycline therapy. </item>
                     <item>Advise patients to take ORACEA exactly as directed. Increasing doses beyond 40 mg every morning may increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the future.</item>
                  </list>
               </text>
               <effectiveTime value="20220930"/>
            </section>
         </component>
         <component>
            <section ID="ID_4873d3d9-e7af-4d58-9756-c1c42b236281">
               <id root="5760a2fa-90fc-49b8-9eb3-4d87ddd76f7c"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>
                  <content styleCode="bold">PATIENT INFORMATION</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">ORACEA (Or-RAY-sha)</content>
                     <br/>
                     <content styleCode="bold">(doxycycline) </content>
                     <content styleCode="bold">capsules</content>
                  </paragraph>
                  <paragraph>Read this Patient Information before you start taking ORACEA and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is ORACEA?</content>
                     <br/>ORACEA is a tetracycline-class medicine. ORACEA is a prescription medicine used in adults to treat only pimples or bumps (papules and pustules) caused by a condition called rosacea. ORACEA does not lessen redness caused by rosacea. <br/>ORACEA should not be used for the treatment or prevention of infections.<br/>It is not known if ORACEA is:<br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>effective for use for longer than 16 weeks. </item>
                     <item>safe for use longer than 9 months. </item>
                     <item>safe and effective in children. ORACEA should not be used in infants and children less than 8 years of age because it may cause stained teeth in infants and children.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Who should not take ORACEA?</content>
                     <br/>Do not take ORACEA if you are allergic to doxycycline or other medicines in the tetracycline-class. Ask your doctor or pharmacist for a list of these medicines if you are not sure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking ORACEA?</content>
                     <br/>Before you take ORACEA tell your doctor if you:</paragraph>
                  <list listType="unordered">
                     <item>have kidney problems.</item>
                     <item>have liver problems.</item>
                     <item>have diarrhea or watery stools. </item>
                     <item>have vision problems. </item>
                     <item>have had surgery on your stomach (gastric surgery). </item>
                     <item>have or had a yeast or fungal infection in your mouth or vagina. </item>
                     <item>have any other medical condition. • are pregnant or plan to become pregnant. ORACEA may harm your unborn baby. Taking ORACEA while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Stop taking ORACEA and call your doctor right away if you become pregnant while taking ORACEA. </item>
                     <item>are breastfeeding or plan to breastfeed. ORACEA can pass into your breast milk and may harm your baby. Talk to your doctor about the best way to feed your baby if you take ORACEA. You and your doctor should decide if you will take ORACEA or breastfeed. You should not do both.</item>
                  </list>
                  <paragraph>Tell your doctor about all of the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. ORACEA and other medicines can affect each other causing serious side effects. <br/>
                     <br/>
                     <content styleCode="bold">Especially tell your doctor if you take:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>a blood thinner medicine. </item>
                     <item>a penicillin (antibacterial medicine). </item>
                     <item>proton pump inhibitors or antacids that contain aluminum, calcium, or magnesium. </item>
                     <item>products containing iron or bismuth subsalicylate. </item>
                     <item>a medicine taken by mouth that contains isotretinoin or acitretin. </item>
                     <item>a medicine to treat seizures, such as carbamazepineor or phenytoin.</item>
                  </list>
                  <paragraph>Ask your doctor or pharmacist for a full list of these medicines, if you are not sure. <br/>
                     <br/>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take ORACEA?</content>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Take ORACEA exactly as prescribed by your doctor. Taking more than your prescribed dose may increase your chance of side effects, including the chance that bacteria will become resistant to ORACEA. </item>
                     <item>Take ORACEA 1 time a day in the morning on an empty stomach. </item>
                     <item>You should take ORACEA at least one hour before or two hours after a meal. </item>
                     <item>Take ORACEA with enough fluid to completely swallow the capsule and to lower your risk of getting irritation or ulcer in your esophagus. Your esophagus is the tube that connects your mouth to your stomach. </item>
                     <item>If you took too much ORACEA call your doctor right away. </item>
                     <item>Your doctor may do blood tests during treatment with ORACEA to check for side effects.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking ORACEA?</content>
                     <br/>Avoid sunlight or artificial sunlight, such as a tanning booth or sunlamp. You could get severe sunburn. Use sunscreen and wear clothes that cover your skin while out in sunlight.  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of ORACEA?</content>
                     <br/>ORACEA may cause serious side effects, including:<br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Harm to an unborn baby.</content> See “<content styleCode="bold">What should I tell my doctor before taking ORACEA?</content>” </item>
                     <item>P<content styleCode="bold">ermanent teeth discoloration</content>. ORACEA may permanently turn a baby or child's teeth yellow-grey-brown during tooth development. ORACEA should not be used during tooth development. Tooth development happens in the last half of pregnancy, and from birth to 8 years of age. See “What should I tell my doctor before taking ORACEA?” </item>
                     <item>
                        <content styleCode="bold">Intestine infection (pseudomembranous colitis).</content> Pseudomembranous colitis can happen with most antibiotics, including ORACEA. Call your doctor right away if you get diarrhea or bloody stools. </item>
                     <item>I<content styleCode="bold">mmune system reactions including a lupus-like syndrome, hepatitis,and inflammation of blood or lymph vessels (vasculitis). </content>Stop taking ORACEA and tell your doctor right away if you get joint pain, fever, rash, or body weakness. </item>
                     <item>
                        <content styleCode="bold">Discoloration (hyperpigmentation). </content>ORACEA can cause darkening of your skin, scars, teeth, gums, nails, and whites of your eyes. </item>
                     <item>
                        <content styleCode="bold">Benign intracranial hypertension, also called pseudotumor cerebri.</content> This is a condition where there is high pressure in the fluid around the brain. This swelling may lead to vision changes and permanent vision loss. Stop taking ORACEA and tell your doctor right away if you have blurred vision, vision loss, or unusual headaches</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">The most common side effects of ORACEA include:</content>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>soreness in the nose and throat</item>
                     <item>sinus infection </item>
                     <item>fungus infection </item>
                     <item>flu-like symptoms </item>
                     <item>diarrhea </item>
                     <item>stomach (abdominal) bloating or pain </item>
                     <item>high blood pressure (hypertension) </item>
                     <item>change in certain blood tests</item>
                  </list>
                  <paragraph>Tell your doctor if you have any side effect that bothers you or that does not go away. <br/>
                     <br/>These are not all the possible side effects of ORACEA. For more information, ask your doctor or pharmacist. <br/>
                     <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  You may also report side effects to Galderma Laboratories, L.P. at 1-866-735-4137</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store ORACEA?</content>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Store ORACEA at room temperature between 59°F to 86°F (15°C to 30°C). </item>
                     <item>Keep ORACEA in a tightly closed container. </item>
                     <item>Keep ORACEA inside container and out of light.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep ORACEA and all medicine out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about ORACEA</content>
                     <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take ORACEA for a condition for which it was not prescribed. Do not give ORACEA to other people, even if they have the same symptoms you have. It may harm them.<br/>
                     <br/>This Patient Information leaflet summarizes the most important information about ORACEA. If you would like more information, talk with your doctor. You can also ask your doctor or pharmacist for information that is written for health professionals.<br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in ORACEA?</content>
                     <br/>Active ingredient: doxycycline<br/>Inactive ingredients: hard gelatin capsule, hypromellose, methacrylic acid copolymer, Opadry beige, sugar spheres, talc, and triethyl citrate.<br/>
                  </paragraph>
                  <paragraph>Marketed by:<br/>Galderma Laboratories, L.P.<br/>Dallas, Texas 75201 USA<br/>
                     <br/>All trademarks are the property of their respective owners.<br/>PXXXXX-X</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration. <br/>Revised: April 2025</paragraph>
               </text>
               <effectiveTime value="20250404"/>
            </section>
         </component>
         <component>
            <section ID="ID_079bdd6c-2b08-4afa-8f4a-a6552da6a2b1">
               <id root="fb8ed869-b728-483a-9133-ef84612a4fe8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL</title>
               <text>
                  <renderMultiMedia referencedObject="SPLSERV-174d9e3c-335f-4143-8efe-1d2573dc6f92"/>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 0299-3822-30</paragraph>
                  <paragraph>
                     <content styleCode="bold">ORACEA<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">   (doxycycine, USP)<br/>capsules   </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">40 mg<sup>*</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <sup>*</sup>30 mg IMMEDIATE RELEASE &amp;<br/>10 mg DELAYED RELEASE BEADS</paragraph>
                  <paragraph>
                     <content styleCode="bold">30 CAPSULES</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">RX ONLY</content>
                  </paragraph>
                  <paragraph>GALDERMA</paragraph>
                  <paragraph>Marketed by:<br/>Galderma Laboratories, L.P.<br/>Dallas, TX 75201 USA<br/>
                     <br/>All trademarks are the property of their respective owners.<br/>oracea.com<br/>P56801-1</paragraph>
               </text>
               <effectiveTime value="20220930"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>